SCHEMBL30770403

SCHEMBL30770403

NS(=O)(=O)c1ccc2c(c1)CN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.65
ESR2 Q92731 5/20 0.65
CA1 P00915 7/20 0.63
CA2 P00918 7/20 0.63
CA7 P43166 7/20 0.63
CA9 Q16790 6/20 0.63
CA12 O43570 2/20 0.63
PKM P14618 1/20 0.61
CA14 Q9ULX7 6/20 0.53
CPT2 P23786 1/20 0.46
CPT1A P50416 1/20 0.46
ABHD6 Q9BV23 3/20 0.44
PNMT P11086 2/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
NR1H2 P55055 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20681402 1.00 ESR1 (0.65) ESR1ESR2CA1CA2CA7
SCHEMBL2993408 0.89 ESR1 (0.68) ESR1ESR2CA1CA2CA7
SCHEMBL11477876 0.88 ESR1 (0.67) ESR1ESR2CA1CA2CA7
SCHEMBL490066 0.87 ESR1 (0.65) ESR1ESR2CA1CA2CA7
SCHEMBL8277232 0.87 ESR1 (0.65) ESR1ESR2CA1CA2CA7
SCHEMBL30408119 0.87 ESR1 (0.65) ESR1ESR2CA1CA2CA7
Dimethylamine SCHEMBL6529354 0.85 ESR1 (0.62) ESR1ESR2CA1CA2CA7
SCHEMBL4231312 0.84 ESR2 (0.68) ESR1ESR2CA1CA2CA7
SCHEMBL6297841 0.84 ESR1 (0.61) ESR1ESR2CA1CA2CA7
SCHEMBL10154278 0.84 ESR1 (0.61) ESR1ESR2CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4349820-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2024-04-10 EP disclosed
EP-3658539-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-02-21 EP disclosed
EP-3880659-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-01-03 EP disclosed